Agenus brain cancer vaccine nearly doubles survival rate in study

Send a link to a friend  Share

[July 01, 2014]  (Reuters) - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.

The drug, when given in addition to standard treatment, extended median overall survival in 50 percent of newly-diagnosed glioblastoma multiforme (GBM) patients to two years in a mid-stage study.

Usually GBM patients succumb to the disease in one year.

(Reporting by Natalie Grover in Bangalore; Editing by Joyjeet Das)
 

[to top of second column]

[ 2014 Thomson Reuters. All rights reserved.]

Copyright 2014 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

< Recent articles

Back to top